MedPath

Prospective randomized controlled trial study of Luofengning Granule in the treatment of unstable angina

Phase 1
Not yet recruiting
Conditions
nstable angina
Registration Number
ITMCTR2000003090
Lead Sponsor
Xian Wang
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Confirmed UA patients;
2. Aged 18 to 80 years;
3. No gender restriction;
4. According to the requirements of GCP, the subjects will sign the informed consent form knowingly and voluntarily.

Exclusion Criteria

1. Patients with diagnosis of AMI, stroke or undergone PCI or coronary artery bypass grafting (CABG) within 1 month prior to enrollment;
2. Patients with coexistent severe heart failure (NYHA, Class IV) and severe arrhythmia (atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, sinus bradycardia (heart rate < 55), complete left bundle branch block;
3. With combined liver and kidney dysfunction, liver function (ALT, AST) 3 times higher than the upper limit of normal renal function, creatinine clearance rate (CrCl) less than 30 ml/min/1.73m2;
4. With poorly controlled hypertension (systolic pressure >= 160mmHg or diastolic blood pressure >= 100mmHg);
5. With the terminal phase cachexia of malignant tumors;
6. With high bleeding risk,such as history of hemorrage of vital organs (brain or upper gastrointestinal tract) within 6 months, low platelet counts, abnormal coagulation function, recent active hemorrhage,etc.;
7. Patients with bleeding tendency within 1 month after operation;
8. Women who are under breastfeeding, pregnant or preparing for pregnancy;
9. With poor compliance;
10. Patients with known or suspected allergy to the test drug or allergic constitution;
11. Patients who participate in any other clinical study or take any of its investigational drugs within the last three months.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
Âİ Copyright 2025. All Rights Reserved by MedPath